Trial Profile
Efficacy and safety of gefitinib monotherapy for all types of refractory cancer patients with EGFR amplification
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Jun 2022
Price :
$35
*
At a glance
- Drugs Gefitinib (Primary)
- Indications Gastric cancer; Glioblastoma; Rectal cancer; Sarcoma; Solid tumours; Squamous cell cancer
- Focus Therapeutic Use
- 13 Jun 2022 Status changed from recruiting to completed.
- 27 Feb 2020 Results (n=15) of use of Gefitinib in EGFR-Amplified refractory solid tumors has been published in the Targeted Oncology.
- 17 May 2019 Planned End Date changed from 1 Dec 2018 to 1 Dec 2020.